Efficacy of finerenone in patients with type 2 diabetes, chronic kidney disease and altered markers of liver steatosis and fibrosis: A FIDELITY subgroup analysis
Authors' conclusion
Finerenone has neutral effects on liver parameters in patients with chronic kidney disease and type 2 diabetes. Finerenone showed robust and consistent kidney benefits in patients with altered liver tests, and profound cardiovascular benefits even in patients with higher FIB-4 scores who were at high risk of developing cardiovascular complications.
Study context
- Population
- Patients with CKD and T2D, stratified by liver steatosis risk (hepatic steatosis index >36), elevated transaminases (alanine transaminase (ALT) >33 IU/L males, >25 IU/L females) and FIB-4 index >3.25, >2.67 and >1.30
- Participants
- 13,026 patients
- Comparison
- Finerenone vs placebo
- Outcome
- Composite CV outcome by FIB-4 subgroup
Methodological detailspost hoc, subgroup analysis
- Post hoc
- Subgroup analysis
Pooled result
As reported in the abstract
Risk reduction with finerenone vs placebo, FIB-4 >3.25 (P for interaction = .01)
52%
Risk reduction with finerenone vs placebo, FIB-4 >2.67 (P for interaction = .13)
39%
Risk reduction with finerenone vs placebo, FIB-4 >1.30 (P for interaction = .03)
24%
Safety
Liver enzymes (ALT, AST, GGT)
- ALT, AST and GGT levels consistent between treatment groups and stable throughout
Original publication
Composed by AI from the published abstract and checked against it. How Briefs are made →